Launch of lung cancer drug could add $15 mn in revenue: Arpit J Vyas, Dishman Pharma

The lung cancer drug, if it is launched, could help the company add up to $15 million in revenues annually, says Arpit J Vyas, MD, Dishman Pharma. In an interview with ET Now, the company's MD clarifies that things are taken care of by its US-based subsidiary Clovis.

ET Now: Clovis is witnessing a big setback. Tell us about the supply of API to your client.

Arpit J Vyas: For this drug the API has to be supplied by our subsidiary company because they have the deal with them right now. When the product launches and the volume increases, that is when we were going to be supplying to them at a later on phase.

As of now we are not doing Dishman India is not doing anything, it is all happening at the subsidiary level. If the drug goes to launch, and as I said that after launch the peak time comes after three or four years, we would be expecting revenue of around $15 million.